1. Introduction {#s0005}
===============

Enteral feeds for children with severe organic acidaemias, (propionic acidaemia, \[PA\]; vitamin B~12~ non-responsive methyl malonic acidaemia, \[MMA B~12~nr\]; isovaleric acidaemia, \[IVA\]; glutaric aciduria type 1, \[GA1\]); dependent on tube feeding are complex. Protein-free composite feeds supplying adequate macro and micronutrients are unavailable for children over 12 months of age, necessitating feeding regimens to consist of multiple ingredients to meet the non-protein nutritional requirements. Adaptation of enteral formulations designed for other clinical conditions may lead to nutritional imbalance, sub-optimal growth and body composition in children who are at risk of metabolic decompensation. It is essential to provide an age appropriate, protein-free composite feed to supplement sources of natural and precursor-free L-amino acid supplements for enteral feeds in this vulnerable group.

Our hypothesis was that an age appropriate protein-free composite feed (supplemented with fat, carbohydrate, vitamins, minerals and essential fatty acids) formulated for children over the age of 1 year with IMD would improve nutritional status and simplify enteral tube feeding regimens for children requiring low protein diets with organic acidaemias. The protein-free composite feed was designed to accompany a protein containing feed, which supplied the protein source.

We have previously reported the short-term efficacy and tolerance of a powdered pre-measured protein-free composite feed \[Basecal 200 Vitaflo Ltd. Liverpool UK\], containing fat, carbohydrate and micronutrients designed for children with organic acidaemias, over 1 year of age. The children required a protein restriction, and were tube feeding dependent. In this open, extension study, we report the nutritional efficacy and caregiver feed preparation data after the protein-free composite feed formulated for children aged over 1 year of age had been used for 18 months when patients were fully transitioned onto the protein-free composite feed. This protein- free feed provided energy and an important source of carbohydrate, fat, essential fatty acids, vitamins and minerals. The protein requirements were provided by a separate feed and we were not aiming to study the impact on protein nutrition.

2. Methods {#s0010}
==========

2.1. Study design {#s0015}
-----------------

An 18-month, longitudinal prospective open-label, intervention, extension study using a protein-free composite feed (study feed) developed for children over 1 year of age. The introduction of the study feed in the first 6 months (phase 1) has been reported [@bb0005]. In phase 2, patients with organic acidaemias on tube feeds were studied for a further 12 months, when all individual modular energy sources were replaced with only one ingredient, the study feed

2.2. Study formulation ([Table 1](#t0005){ref-type="table"}) {#s0020}
------------------------------------------------------------

The pre-measured study feed has a nutritional profile that meets the nutritional requirements of children over 1 year of age when reconstituted at 1 kcal/ml. It contains carbohydrate, fat (including long chain polyunsaturated fatty acids), vitamins, minerals, and trace elements. It does not contain fibre. Each sachet (43 g) mixed with 200 ml water, provides 200 kcals (1 kcal/ml).Table 1A comparison of the nutritional composition (per 100 ml and per 100 Kcal) of study protein-free module ingredient (Basecal) with a protein-free infant feed (Energivit).Table 1Basecal 200 (Vitaflo Ltd) per 100 Kcal equivalent to 100 mlEnergivit (Nutricia) per 100 ml (15% dilution as recommended by manufacturer)Energivit (Nutricia) per 100 Kcal equivalent to 20% dilution. NB. This is in excess of manufacturers recommendationEnergy Kcal/kJ100/42074/309100/420Protein g000Carbohydrate g151013.3Fat g4.53.85.1Vitamin A μg6558.878.4Vitamin D μg1.71.31.7Vitamin E mg211.3Vitamin C mg157.410Vitamin K μg5.75.67.5Thiamin mg0.110.080.1Riboflavin mg0.160.080.1Niacin mg1.11.11.5Vitamin B6 mg0.130.080.1Folic acid μg18.58.311.1Vitamin B 12 μg0.280.20.27Iron mg11.21.6Zinc mg10.91.2Copper mg0.070.070.09Selenium μg32.33Magnesium mg10.28.711.6Manganese mg0.10.060.08Biotin μg3.52.73.6Pantothenic acid mg0.550.40.5Sodium mmol1.81.21.6Potassium mmol2.51.92.5Chloride mmol1.61.52Phosphorous mg1.31.52Iodine μg1712.517Molybdenum μg4.81.82.4Choline mg20.613.718.3Inositol mg1114.719.6DHA mg1600AAmg1600

2.3. Inclusion criteria {#s0025}
-----------------------

Children were recruited if they had a proven organic acidaemia, aged over 1 years of age or weighed between 8 and 31 kg, and were taking a modular feed providing ≥ 75% of enteral feed intake. All children had taken part in study phase 1 [@bb0005].

2.4. Phased introduction of study feed ([Table 2](#t0010){ref-type="table"}) {#s0030}
----------------------------------------------------------------------------

At the start of the study, when analysis is based on the follow-up subjects (n = 13), enteral feeds consisted of a median of 4 ingredients comprising of: a natural protein source, precursor-free [l]{.smallcaps}-amino acids (disorder specific) and energy modules (either an infant energy module \[± additional energy modules\] or individual energy modules).Table 2Type of feed ingredients used and method of measurement at baseline phase 1 and phase 2 for n = 13 subjects.Table 2Feed ingredientMeasurementPre study (week 8)Phase (week 0--26)Phase 2 (week 27--79)Natural protein sourceNutrini multifibre[a](#tf0005){ref-type="table-fn"}Liquidn = 9n = 9n = 11Tentrini multifibre[a](#tf0005){ref-type="table-fn"}Liquidn = 2n = 2n = 2Standard whey based infant formula (Cow and Gate)[a](#tf0005){ref-type="table-fn"}Scalesn = 2n = 2n = 0Precursor-free [l]{.smallcaps}-amino acidsMMA/PA amino 5[b](#tf0010){ref-type="table-fn"}Sachetn = 6n = 10n = 10GA amino acids[b](#tf0010){ref-type="table-fn"}Sachetn = 1n = 1n = 1MMA/PA anamix infantScalesn = 4Energy sourceEnergivit[a](#tf0005){ref-type="table-fn"}Scalesn = 11Study feed[b](#tf0010){ref-type="table-fn"}Sachetsn = 13n = 13Glucose polymer, (Maxijul)[a](#tf0005){ref-type="table-fn"}Scalesn = 9Glucose polymer, (SOS)[b](#tf0010){ref-type="table-fn"}Sachetsn = 850% fat emulsion, (Calogen)[a](#tf0005){ref-type="table-fn"}Liquidn = 1n = 1Vitamins and mineral supplementVitamin and mineral supplement, Paediatric Seravit[a](#tf0005){ref-type="table-fn"}Scalesn = 1FibreSoluble fibre, Optifibre[c](#tf0015){ref-type="table-fn"}Sachetn = 1n = 1n = 4Median number (range) of feed ingredientsn = 4 (1--5)n = 3 (1--4)n = 3 (1--4) [\*](#tf0020){ref-type="table-fn"}p = 0.05[^1][^2][^3][^4][^5]

### 2.4.1. Phase 1 (week 0--26) {#s0035}

In this phase, the aim was to ensure children tolerated the study feed. This feed replaced the infant protein-free composite feed (Energivit \[Nutricia Ltd\]). However, to maintain a constant energy intake supporting metabolic stability, other energy sources \[glucose polymer (n = 8) and 50% fat emulsion (n = 1)\] remained in the feed recipes. All precursor-free [l]{.smallcaps}-amino acids were changed to pre-measured sachets. (Vitaflo International Ltd)

### 2.4.2. Phase 2 (week 27--79) {#s0040}

The study protein-free composite feed completely replaced the remaining energy sources (glucose polymer and 50% fat emulsion).

2.5. Protein prescription {#s0045}
-------------------------

Changes were made to protein (intake/sources) as children increased in age (e.g. natural protein source changed from infant formula to standard enteral feed). Natural protein was prescribed according to WHO/FAO/UNU (2007) [@bb0010] safe levels of protein intake for MMA/PA and IVA and in GA1 according to European guidelines [@bb0015]. In MMA/PA, an additional 15 to 20% of total protein intake was prescribed from MMA/PA precursor-free L-amino acids (AA); in GA1, lysine-free, low tryptophan AA supplements were prescribed according to GA1 European guidelines [@bb0015]. No precursor-free AA supplements were prescribed for patients with IVA.

2.6. Dietary analysis {#s0050}
---------------------

For 3 days during week 79, caregivers recorded the volume of modular feed consumed and any oral food and drink intake (n = 1) by weighing dietary intake. Dietary analysis was calculated using the software program *Electronic Dietetic Manager* (EDM 2000™ Microman 2000 PO box 3721 Newport Pagnell UK) and McCance and Widdowson\'s 'The Composition of Foods.' [@bb0020]. The intake of energy, total protein (natural protein and protein equivalent from precursor-free [l]{.smallcaps}-amino acids), fibre, calcium, magnesium, iron, zinc, selenium, sodium, potassium, vitamin B~12~, vitamin D, essential fatty acids (DHA and AA) and fluid was assessed. Each nutrient (except protein, essential fatty acids (DHA and AA), fluids and fibre) was compared as a percentage of the DH 1991 reference nutrient intakes (RNI) or estimated average requirement (EAR) for energy [@bb0025] Protein intake was compared with the WHO/FAO/UNU safe levels of protein intake [@bb0010] and fibre with the Scientific Advisory Committee on Nutrition [@bb0030]. Nationally agreed definitions for DHA and AA intake for children in the UK are not available. A comparison was made with World Health Organization [@bb0035] global recommendations.

2.7. Anthropometric measurements {#s0055}
--------------------------------

Weight, height/length, z-scores were collected at outpatient clinic appointments. In children ≥ 2 years of age, weight was estimated by: *standing* and *sitting* Seca electronic scales (accurate to two decimal places); and height by a calibrated stadiometer (accurate to one decimal place). In children \< 2 years of age, measurements were taken naked: weight by Seca infant scales accurate to two decimal places, supine length on a Seca measuring mat accurate to one decimal place.

2.8. Illness episodes {#s0060}
---------------------

The number of hospital admissions, reason for admission and length of stay were recorded from phase 1 (week 0--26) and phase 2 (27--79).

2.9. Nutritional blood biochemistry {#s0065}
-----------------------------------

Venous blood samples were collected for glucose, electrolytes, full blood count, plasma selenium glutathione peroxidase, zinc, iron, ferritin, vitamin B~12~, plasma MMA, and C-reactive protein (CRP) at week − 8, 0, 12, 26. At week 79, venous samples were taken for full blood count, zinc, selenium, ferritin and CRP. Additionally, a random urine test analyzing sodium and potassium concentrations was collected at week 79, as dietary sodium intake was low in phase 1. Blood samples were taken after a minimum of 3 h fasting

2.10. Statistics {#s0070}
----------------

The median nutritional intake from the different feeding regimens was compared at baseline, week 26 and week 79. The statistical tests used were non-parametric paired Wilcoxon signed rank tests. The same statistical tests were applied to analyse for significant differences in biochemistry, haematology and anthropometric results.

3. Results {#s0075}
==========

3.1. Subjects ([Table 3](#t0015){ref-type="table"}) {#s0080}
---------------------------------------------------

Thirteen children (6 boys, 7 girls) were followed from phase 1. Confirmation of the organic acidaemia by DNA analysis is available for nine of the thirteen subjects. One subject had confirmation via skin biopsy and isovaleric acid incorporation analysis; the remaining three subjects were diagnosed by routine biochemical testing. Their median age (range) was 7.4y (3--15.5y). All had organic acidaemias: PA n = 6; MMA B~12~nr, n = 4; IVA n = 2; and GA1, n = 1. Eight children were of Asian Pakistani origin, one Afro-Caribbean, one Arabic, one Bangladeshi and two European. All children received ≥ 75% of their enteral nutritional intake via tube feeds (nutritional intake: ≥ 90%, n = 12; 75%, n = 1). Two children, both with PA were withdrawn from the study after completing phase 1 (one died post liver transplantation and one required long term hospital intensive care management).Table 3DNA mutation analysis results for subjects participating in the modular feed study.Table 3Subject numberDNA mutation confirmationDiagnosis1.Homozygous c.937C \> T (p.Arg313X)PA2.Homozygous c.937C \> T p.(Arg313\*)PA3.Homozygous c.1288C \> TPA4.Homozygous C.11.120786 c.1746 + 1G \> APA5.Homozygous C.1498 + 2T \> CPA6.Confirmed by biochemical testingPA7.Homozygous c.09.4018 MUT gene c.1106G \> A p.(Arg369His)MMAmut^0^8.Two homozygous variants in Mut gene c.689C \> G p(Thr230Arg) and c. 1991C \> T p.(Ala664 Val)MMA mut^0^9.Skin biopsy activities of holomutase severely deficient both in fiboblasts cultured in MEM with or without B12. Defect of methymalonyl CoA mutase apoenzyme.MMA mut^0^10.Confirmed by biochemical testingMMA11.Compound heterozygous in GCDH gene c.572T \> C and c.304delGGA112.Skin biopsy isovaleric acid incorporation analysisIVA13.Confirmed by biochemical testingIVA

Twelve children had a gastrostomy tube/button and one had a nasogastric tube. Eleven families had one caregiver who spoke and read English fluently. Diagnosis was mainly in the neonatal period (including three siblings of index cases), but 2 were diagnosed later in infancy (7 months \[*n* = 1\] and 10 months \[*n* = 1\]).

3.2. Feed preparation changes ([Table 2](#t0010){ref-type="table"}) {#s0085}
-------------------------------------------------------------------

The number of enteral feed ingredients decreased significantly in phase 2: median number of ingredients baseline, n = 4; phase 1, n = 3; and phase 2, n = 3; \[p = 0.05\]. In phase 2, no caregivers used scales or scoops to measure ingredients.

3.3. Nutrient intake ([Table 4](#t0020){ref-type="table"}) {#s0090}
----------------------------------------------------------

### 3.3.1. Energy, protein and fluid intake {#s0095}

Energy intake (median of 76%) as a percentage of the estimated average requirement (EAR) for age [@bb0025] remained unchanged between baseline, phase 1 and phase 2. The energy intake was closely controlled to avoid excessive weight gain.Table 4Comparison of daily nutritional intake and reference nutrient intakes, median (range) for all nutrients measured at baseline, phase 1 (when study feed replaced one ingredient), and phase 2 (when all modular ingredients were replaced).Table 4NutrientsMean nutrient intake (range)Significance\
Pre-study to phase 1\
n = 13Mean nutrient intake (range)\
Phase 2\
(week 79)Significance\
Baseline to phase 2\
n = 13% reference nutrient intakeSignificance\
Pre-study to phase 1\
n = 13% reference nutrient intake\
Phase 2 (week 79)Significance\
Baseline to phase 2\
n = 13Pre-study\
(week 8)Phase 1\
(week 26)Baseline\
(week 8)Phase 1\
(week 26)Energy kcal/kg/d^\*^59 (32--82)61 (34--87)p = 0.8748 (33--62)p = 0.00276 (47--103)78 (46--98)p = 0.0676 (48--86)p = 0.4Total protein g/kg (natural and precursor-free [l]{.smallcaps}-amino acids) g/kg/d1.2 (0.7--1.5)1.2 (0.8--1.4)p = 0.481.0 (0.6--2.1)p = 0.002129 (78--153)127 (88--164)p = 0.32111 (67--200)p = 0.002Natural protein^\*\*^ g/kg/d0.85 (0.5--1.2)0.85 (0.5--1.2)p = 0.30.9 (0.6--1.1)p = 0.894 (56--141)91 (56--118)p = 0.56100 (82--130)p = 0.8Precursor-free [l]{.smallcaps}-amino acids g/kg/d0.35 (0.2--0.7)0.4 (0.2--0.6)p = 0.80.2 (0--1)p = 0.002n/an/an/aCalcium mg/d^\*\*\*^693 (426--848)718 (498--1102)p = 0.39804 (569--1673)p = 0.02145 (89--242)152 (95--247)p = 0.43153 (88--200)p = 0.9Iron mg/d^\*\*\*^12 (6--17)12 (6--18)p = 0.7513.7 (10--27)p = 0.02142 (87--232)147 (87--197)p = 0.75161 (95--260)p = 0.4Zinc mg/d^\*\*\*^10.5 (6--14)11.5 (6--17)p = 0.1513.7 (10--26)p = 0.0005149 (92--240)179 (120--243)p = 0.15183 (138--289p = 0.06Selenium μg/d^\*\*\*^30.2 (15--46)35.5 (17--68)p = 0.1241 (29--71)p = 0.005148 (87--247)168 (84--213)p = 0.1137 (93--195)p = 0.6Phosphorous mg/d^\*\*\*^508 (308--749)553 (291--832)p = 0.37634 (445--1231)p = 0.001144 (93--214)148 (95--211)p = 0.36153 (95--250)p = 0.8Potassium mmol/d^\*\*\*^26.9 (16--46)28 (15--48)p = 0.237 (26--63)p = 0.00591 (28--164)102 (33--164)p = 0.0674 (49--143)p = 0.4Vitamin D μg/d^\*\*\*^13 (8--17)15.7 (12--24)p = 0.0416 (11--29)p = 0.14179 (114--242)214 (171--257)p = 0.1na^\$^naMagnesium mg/d^\*\*\*^100 (67--173)121 (57--278)p = 0.02145 (102--392)p = 0.00577 (43--144)102 (49--135)p = 0.0289 (54--140)P = 0.08Vitamin B 12 μg/d^\*\*\*^2.7 (1.7--3.6)3.0 (2--5)p = 0.013.0 (3--6)p = 0.003339 (200--580)388 (280--580)p = 0.04375 (200--600)p = 0.6Sodium mmol/d^\*\*\*^20 (8--33)25 (9--36)p = 0.00231 (22--42)p = 0.00161 (29--110)72 (34--110)p = 0.00580 (53--127)p = 0.03Docosahexaenoic acid (mg)^§^0 (0--340)96 (32--340)p = 0.01113 (44--369)p = 0.00010 (0--170)48 (16--170)p = 0.00557 (22--185)p = 0.002Arachidonic acid (mg)0 (0--91)96 (32--128)p = 0.00195 (45--121)p = 0.0005n/an/an/aFluid ml/kg/d^§§^1087 (630--1430)1100 (700--1430)p = 0.11200 (900--1890)p = 0.000568 (39--89)69 (44--89)p = 0.270 (53--98)p = 0.9Fibre g/d^§§§^4 (0 − 12)4 (0--12)p = 14 (0--12)p = 120 (0--60)20 (0 = 60)p = 120 (0 = 60)p = 1[^6]

### 3.3.2. Protein intake {#s0100}

The median natural protein intake remained constant at 0.9 g/kg/day throughout the 18-month study period. Total protein intake expressed as g/kg/day significantly decreased, (p = 0.002) associated with decreasing natural protein requirements with age (WHO/FAO/UNU 2007) [@bb0010] and a corresponding decrease in precursor-free L-AA (p = 0.002) from baseline to week 79. Natural protein intake was provided from a standard paediatric feed Nutrini multifibre (Nutricia Ltd., Trowbridge, UK), meeting safe levels of protein intake. Precursor-free amino acids supplemented natural protein intake, providing an additional 15 to 20% of total protein intake.

### 3.3.3. Vitamin, mineral and long chain fatty acid intake ([Table 4](#t0020){ref-type="table"}) {#s0105}

From baseline to week 79 there was a significant increase in the median daily intake of: calcium \[p = 0.02\], iron \[p = 0.02\], zinc \[p = 0.0005\], selenium \[0.005\], phosphorous \[0.001\], vitamin B~12~ \[p = 0.003\], potassium \[0.005\], magnesium \[p = 0.005\], and sodium \[p = 0.001\]. The intake of both docosahexaenoic acid (DHA) \[p = 0.0001\] and arachidonic acid (AA) \[p = 0.0005\] significantly improved. Nutrients failing to meet reference intakes were potassium (74%), magnesium (89%), sodium (80%), docosahexaenoic acid (DHA) 57% and fibre (20%).

In phase 1, dietary intake of only magnesium \[p = 0.02\], sodium \[p = 0.002\], Vitamin B~12~ (p = 0.01), Vitamin D (p = 0.04), docosahexaenoic acid (DHA) \[p = 0.01\] and arachidonic acid (AA) \[p = 0.001\] significantly improved. All except sodium (72%), DHA (48%) and fibre (20%) failed to meet reference guideline intakes.

3.4. Nutritional biochemical and haematology results ([Table 5](#t0025){ref-type="table"}) {#s0110}
------------------------------------------------------------------------------------------

Over the 18-month period (baseline to week 79), there was a significant increase in plasma zinc \[p = 0.03\], selenium \[p = 0.01\], haemoglobin \[p = 0.05\] and MCV \[p = 0.005\]. All the other measured analytes, ferritin and CRP remained within the reference ranges and were unchanged. Median urinary sodium was 80 mmol/L (22 − 300) and potassium was 41 mmol/L (13--236), with an appropriate ratio of 2:1.Table 5Median biochemical and haematological (range) values with study feed replacing one ingredient and after 18 months when all modular ingredients replaced.Table 5Pre-study (week − 8) median (range)Phase 1 (week 26) median (range)Statistical significance pre-study to phase 1 n = 13Phase 2 (week 79) median (range)Statistical significance pre-study to phase 2 n = 13Reference rangePlasma zinc μmol/L10.9 (8.9--14.6)10.7 (7--15.3)p = 0.9812.5 (7--16.5)p = 0.0310--18Plasma selenium μmol/L0.96 (0.6--1.2)1.11 (0.8--1.4)p = 0.0021.2 (0.9--1.5)p = 0.010.8--8.2Ferritin μg/L34 (5.3--121)39.2 (7.8--167)p = 0.1238.5 (9--93)p = 0.832--233Vitamin B12 ng/L957 (208--1049)977 (166--2121)p = 0.95760 (114--1500)p = 0.2259--823Haemoglobin g/dL122.9 (103--139)123.8 (114--136)p = 0.84130 (109--161)p = 0.05112--130MCV g/L75 (65--83)76 (68--84)p = 0.2285 (73--94)p = 0.00575--90C reactive protein mg/L2.6 (1 − 13)2.9 (1--19)p = 0.92.3 (1 − 12)p = 0.9\< 10Urine sodium mmol/L--80 (22--300)40--220Urine potassium mmol/L--41 (13--236)10--60

In phase 1, only plasma selenium \[p = 0.002\] and whole blood glutathione peroxide \[p = 0.02\] significantly improved (baseline to week 26).

3.5. Anthropometry {#s0115}
------------------

There were no significant differences in median height or weight z scores throughout the study. Median weight z score: baseline, 0.3 (− 3.1 to 2.5); phase 2, 0.2 (− 2.3 to 1.8); height z score: baseline, − 1.3 (− 2.6 to 1.5); phase 2, − 0.9 (− 2.9 to 0.4).

3.6. Hospital admissions {#s0120}
------------------------

The median number of hospital admission days was: phase 1, 3 (range 2--12); and phase 2, 3 (range 1--86). The hospital admissions were associated with vomiting, chest infections or pancreatitis (n = 1) causing metabolic decompensation. No admissions were reported because of feed changes.

3.7. Medications {#s0125}
----------------

The median number of daily medications was 4, range (1--10): including [l]{.smallcaps}-carnitine (n = 13), metronidazole (n = 7), domperidone (n = 2), ondansetron (n = 4), omeprazole (n = 4), and ranitidine (n = 1). Six subjects were prescribed regular laxatives (movicol and lactulose) and 4 had fibre added to their feeds for constipation. One child was prescribed sodium supplements because of previous low blood concentrations. Only one child was routinely prescribed sodium benzoate due to frequent metabolic decompensation; no other patients were prescribed ammonia lowering drugs.

4. Discussion {#s0130}
=============

In this longitudinal 18 month study, the use of a pre-measured protein-free composite feed designed for children aged over 1 year used in combination with protein sources (natural protein and precursor-free L-AA) to meet individualized protein requirements improved the nutrient intake and biochemical status in children with organic acidaemias. Replacing individual energy and fat modules with one comprehensive protein-free composite feed simplified the feeding regimens, and overall, lowered the number of core ingredients used.

Over 18 months, there was a significant improvement in the intake of essential fatty acids, vitamins and minerals (calcium, iron, zinc, selenium, phosphorous, vitamin B~12~, potassium, magnesium, sodium and docosahexaenoic and arachidonic acid), which led to an improvement in biochemical nutritional status for plasma zinc, selenium, haemoglobin and MCV. These results were better than we reported in phase 1 of this study. However, in phase 2 (out of controlled study conditions) we were we able to replace all energy supplied by glucose polymer supplements with the nutrient supplemented protein-free composite feed leading to further improvements in nutrient intake. It is essential that patients with organic acidaemias on low protein diets receive optimal nutrition from enteral feeds. They have frequent and unpredictable hospital admissions due to metabolic decompensation and require glucose-polymer based emergency feeds (with a low nutrient density) during intercurrent illness. This interrupts macro and micronutrient supply.

The nutrient composition of the study feed may require further optimization. Magnesium, potassium and sodium intakes were still below the UK RNI [@bb0025]. Only one child, with PA received sodium containing nitrogen scavenger drugs. Although, random sodium and potassium urine analysis in phase 2 suggested an overall satisfactory biochemical status, dietary intakes would imply some children might be borderline deficient. The long-term clinical consequences of these sub-optimal intakes are unknown. Magnesium is physiologically important for skeletal development and maintenance of electrical potential in nerve and muscle membranes [@bb0040]. Potassium is required for lean muscle synthesis, normal cell function and maintenance of total body fluid volume, acid and electrolyte balance. The WHO guideline on potassium intake for adults and children [@bb0045] suggested a conditional recommendation of at least 90 mmol/day, with an adjustment downwards for children based on their energy requirements.

The study feed did not contain a source of fibre. In MMA and PA, the amount and optimal blend of fibre(s) that should be added to enteral feeds is unknown. Mixed fibre supplements in enteral feeds normalises transit time, improves gut barrier function, and increases production of short chain fatty acids especially propionate [@bb0050]. It is possible that adding mixed fibres, particularly those containing neutral sugars to enteral feeds, may increase concentrations of propionate from short chain fatty acids, which may be detrimental in children with PA and MMA [@bb0055], [@bb0060], [@bb0065], [@bb0070]. More information is required about the composition of gut flora in children with OA before optimal fibre(s) amounts and composition can be defined [@bb0075], [@bb0080]. A high number of our study group had chronic issues with constipation and were prescribed regular laxatives.

There were a number of limitations with this study. Due to the rarity of the conditions, it only included a small number of children. We did not measure biochemical fatty acid status. We have also not examined organic acids, protein status or amino acid status as this was not the purpose of this study. Plasma sodium and potassium are not sensitive indices of total body sodium and potassium. Although we did take measurements for urinary sodium and potassium, this was only performed at week 79, and only a single, random sample was taken rather than a 24-h collection to measure 24-h excretion as recommended by the World Health Organization report [@bb0085]. Overall this study cohort was followed up consistently, blood sample timing standardized and any feed changes monitored closely.

This long term follow up study successfully demonstrated that a pre-measured protein-free composite feed used in combination with an enteral protein source for children aged over 1 year with organic acidaemias on low protein enteral feeds, significantly improved nutrient intake, biochemical nutritional status and simplified the feed making process. However, further changes to the nutrient composition of this protein-free composite feed are necessary to deliver the optimal nutritional intake in this group of children, whose nutrient intake may be frequently disrupted as a consequence of illness and metabolic decompensation.
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